https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15748)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15748)2019-05-31 00:00:002020-05-06 15:03:38Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15783)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15783)2019-05-31 00:00:002019-05-31 00:00:00Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e20674)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e20674)2019-05-31 00:00:002019-05-31 00:00:00Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17005)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17005)2019-05-31 00:00:002019-05-31 00:00:00Dynamics of the immune status in patients with cervical cancer receiving complex treatment with dendritic cell vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-29 / Front Oncol 2019;9:436
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-29 / Front Oncol 2019;9:4362019-05-29 00:00:002022-09-29 14:03:17STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-16 / 2019 May;19(1):460
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-16 / 2019 May;19(1):4602019-05-16 00:00:002020-10-05 10:19:52Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-14 / BMJ Open 2019 05;9(5):e026779
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-14 / BMJ Open 2019 05;9(5):e0267792019-05-14 00:00:002019-05-14 00:00:00Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-02 / Crit. Rev. Oncol. Hematol. 2019 Jul;139:67-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-02 / Crit. Rev. Oncol. Hematol. 2019 Jul;139:67-742019-05-02 00:00:002019-05-02 00:00:00Whole-body hyperthermia in combination with systemic therapy in advanced solid malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-01 / Nat. Rev. Cancer 2019 05;19(5):271-282
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-01 / Nat. Rev. Cancer 2019 05;19(5):271-2822019-05-01 00:00:002019-05-01 00:00:00Targeting cancer vulnerabilities with high-dose vitamin C
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-30 / Mol Immunol 2019 07;111:106-117
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-30 / Mol Immunol 2019 07;111:106-1172019-04-30 00:00:002020-12-07 11:34:33A new strategy for enhancing antitumor immune response using dendritic cells loaded with chemo-resistant cancer stem-like cells in experimental mice model
